DNTH
Dianthus Therapeutics Inc

1,250
Mkt Cap
$3.51B
Volume
386,845.00
52W High
$88.02
52W Low
$13.37
PE Ratio
-19.18
DNTH Fundamentals
Price
$79.92
Prev Close
$78.90
Open
$78.72
50D MA
$53.84
Beta
1.04
Avg. Volume
629,526.92
EPS (Annual)
-$4.20
P/B
6.91
Rev/Employee
$22,130.44
$1,188.52
Loading...
Loading...
Poll

Earnings Recap

Dianthus Therapeutics expects to initiate a Phase 3 trial for claseprubart in gMG in mid-2026, with results in H2 2028. The company's existing cash is sufficient to fund operations into 2028.

Bullish

Dianthus Therapeutics achieved positive Phase 2 results for claseprubart in gMG, advanced its Phase 3 trial for CIDP with an early "GO," and expanded its pipeline with DNTH212, initiating Phase 1.

Bearish

Dianthus Therapeutics reported increased net losses in 2025, faces substantial capital requirements, and is exposed to supply chain risks from its sole manufacturer, alongside intense market competition.

Latest DNTH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.